CH574742A5 - - Google Patents

Info

Publication number
CH574742A5
CH574742A5 CH1062271A CH1062271A CH574742A5 CH 574742 A5 CH574742 A5 CH 574742A5 CH 1062271 A CH1062271 A CH 1062271A CH 1062271 A CH1062271 A CH 1062271A CH 574742 A5 CH574742 A5 CH 574742A5
Authority
CH
Switzerland
Application number
CH1062271A
Inventor
Zaffaroni Alejandro
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ZA714095A external-priority patent/ZA714095B/xx
Application filed by Alza Corp filed Critical Alza Corp
Publication of CH574742A5 publication Critical patent/CH574742A5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
CH1062271A 1969-04-01 1971-07-19 CH574742A5 (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81211669A 1969-04-01 1969-04-01
US00042786A US3854480A (en) 1969-04-01 1970-06-02 Drug-delivery system
ZA714095A ZA714095B (en) 1969-04-01 1971-06-22 Bandage for administering drugs
FR7123703A FR2143564A1 (en) 1969-04-01 1971-06-29 Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates

Publications (1)

Publication Number Publication Date
CH574742A5 true CH574742A5 (enExample) 1976-04-30

Family

ID=37734020

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1062271A CH574742A5 (enExample) 1969-04-01 1971-07-19

Country Status (4)

Country Link
US (1) US3854480A (enExample)
CH (1) CH574742A5 (enExample)
DE (1) DE2135533C3 (enExample)
FR (1) FR2143564A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144486A3 (en) * 1983-04-27 1986-05-14 Lohmann Gmbh & Co Kg Controlled-release drugsystem and process for preparing it
AT395815B (de) * 1981-06-29 1993-03-25 Alza Corp Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut

Families Citing this family (628)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4016251A (en) * 1972-08-17 1977-04-05 Alza Corporation Vaginal drug dispensing device
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4014987A (en) * 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4057619A (en) * 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4186745A (en) * 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
DE2650306A1 (de) * 1976-11-02 1978-05-03 Merck Patent Gmbh Antibakteriell wirkender wundverband und verfahren zu seiner herstellung
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4460367A (en) * 1977-06-09 1984-07-17 Alza Corporation Device containing biocide producing paraformalde and an acid
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
EP0009517A1 (en) * 1978-10-04 1980-04-16 THE PROCTER & GAMBLE COMPANY Vaginal contraceptive
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
GB2047543B (en) * 1978-12-06 1983-04-20 Svedman Paul Device for treating tissues for example skin
DE3068649D1 (en) * 1979-03-23 1984-08-30 Upjohn Co Medicated device for controlled drug release
US4308867A (en) * 1979-03-23 1982-01-05 Roseman Theodore J Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals
US4237888A (en) * 1979-03-23 1980-12-09 The Upjohn Company Two-membrane medicated device for rate-controlled administration of prostaglandins
EP0021504B1 (en) * 1979-06-25 1984-10-03 THE PROCTER & GAMBLE COMPANY Article for use as catheter or the like
US4392848A (en) * 1979-06-25 1983-07-12 The Procter & Gamble Company Catheterization
US4343788A (en) * 1979-06-29 1982-08-10 The Procter & Gamble Company Antimicrobial polymer compositions
US4479795A (en) * 1979-06-29 1984-10-30 The Procter & Gamble Company Antimicrobial polymer compositions
PH25589A (en) * 1979-09-12 1991-08-08 Lilly Co Eli Device for drug celivery to ruminants
US4326510A (en) * 1979-11-20 1982-04-27 World Health Organization Barrier contraceptive torus
JPS5777617A (en) * 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
DE3040978A1 (de) * 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
FR2512651B1 (fr) * 1981-06-24 1986-01-17 Pere Lahaille Jeanne Produits anti-rides
USRE34365E (en) * 1981-07-13 1993-08-31 Intravenous system for delivering a beneficial agent
US4973307A (en) * 1981-07-13 1990-11-27 Alza Corporation Method for administering drugs to a patient
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
US5069671A (en) * 1981-07-13 1991-12-03 Alza Corporation Intravenous medication
US4994031A (en) * 1981-07-13 1991-02-19 Alza Corporation Intravenous system for delivering a beneficial agent
US4740201A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4985017A (en) * 1981-07-13 1991-01-15 Alza Corporation Parenteral therapeutical system comprising drug cell
US4511353A (en) * 1981-07-13 1985-04-16 Alza Corporation Intravenous system for delivering a beneficial agent
US4857052A (en) * 1981-07-13 1989-08-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4432756A (en) * 1981-11-27 1984-02-21 Alza Corporation Parenteral controlled therapy
US4790820A (en) * 1981-07-13 1988-12-13 Alza Corporation Parenteral agent dispensing equipment with drug releasing member
US4871360A (en) * 1981-07-31 1989-10-03 Alza Corporation System for intravenous delivery of a beneficial drug at a regulated rates
US4525162A (en) * 1981-07-31 1985-06-25 Alza Corporation Parenteral controlled delivery
US4741735A (en) * 1981-10-09 1988-05-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4740199A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740197A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent via polymer delivery
US4741734A (en) * 1981-10-09 1988-05-03 Alza Corporation Releasing means for adding agent using releasing means to IV fluid
US4740200A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740103A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4586922A (en) * 1981-10-09 1986-05-06 Alza Corporation Intravenous system for delivering a beneficial agent
US4484909A (en) * 1981-11-27 1984-11-27 Alza Corporation Parenteral therapy using solid drug
US4479794A (en) * 1981-11-27 1984-10-30 Alza Corporation System for intravenous therapy
US4579553A (en) * 1981-11-27 1986-04-01 Alza Corporation Parenteral controlled therapy
US4493702A (en) * 1981-11-27 1985-01-15 Alza Corporation Parenteral administration using osmotically motivated delivery system
US4548599A (en) * 1981-11-27 1985-10-22 Alza Corporation Parenteral controlled therapy
US4583981A (en) * 1981-11-27 1986-04-22 Alza Corporation Parenteral controlled therapy, using a porous matrix with parenteral agent
US4479793A (en) * 1981-11-27 1984-10-30 Alza Corporation Parenteral administration using drug delivery device
US4552556A (en) * 1981-11-27 1985-11-12 Alza Corporation Parenteral controlled therapy
US4515585A (en) * 1982-05-24 1985-05-07 Alza Corporation System for parenteral administration of agent
US4664650A (en) * 1982-05-24 1987-05-12 Alza Corporation Apparatus for parenteral infusion of fluid containing beneficial agent
US4908019A (en) * 1982-05-24 1990-03-13 Alza Corporation Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
CA1206049A (en) * 1982-09-30 1986-06-17 Paul E. Michelson Osmotic device for physiological applications
US4709996A (en) * 1982-09-30 1987-12-01 Michelson Paul E Fluid lens
FR2534140B1 (fr) * 1982-10-12 1986-01-31 Fournier Laboratoires Nouveau dispositif pour l'administration percutanee de medicaments
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
FR2538247B1 (fr) * 1982-12-23 1986-05-23 Pere Lahaille Jeanne Pastille anti-rides et/ou traitant la peau
US4469671A (en) * 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
US4623329A (en) * 1983-12-15 1986-11-18 The Procter & Gamble Company Drainage and infusion catheters having a capillary sleeve forming a reservoir for a fluid antimicrobial agent
DE3588023D1 (de) * 1984-01-28 1995-06-29 Roshdy Ismail Mittel zur Behandlung von Herzerkrankungen.
EP0154598B1 (de) * 1984-03-07 1991-12-27 Wolfgang Dr. Holz Verfahren zur Verabreichung von Medikamenten od. dgl. an in Wasserbehältern gehaltene Tiere, insbesondere Fische
US4511352A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system with in-line container
US4511351A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4596555A (en) * 1984-05-14 1986-06-24 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4618487A (en) * 1984-07-06 1986-10-21 Alza Corporation Device for administering calcium ascorbate
DE3447833A1 (de) * 1984-12-29 1986-07-10 Allan Gerhard 8047 Karlsfeld Frühauf Tuch o.dgl. mit einen wirkstoff enthaltenden mikrokapseln
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
US5820876A (en) 1986-08-28 1998-10-13 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system
US6139868A (en) * 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6126963A (en) 1986-08-28 2000-10-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6110488A (en) * 1986-08-28 2000-08-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6117448A (en) * 1986-08-28 2000-09-12 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
DE3629304A1 (de) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
JPH0794384B2 (ja) * 1986-09-01 1995-10-11 帝国製薬株式会社 徐放性口腔内用製剤
DE3750085T2 (de) * 1987-01-09 1994-09-22 Hercon Lab Wasserdampf durchlässiger Verband.
US5322695A (en) * 1987-01-09 1994-06-21 Hercon Laboratories Corporation Moisture-vapor-permeable dressing
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems
DE3823070A1 (de) * 1988-07-07 1990-02-22 Kettelhack Riker Pharma Gmbh Selbstklebendes heftpflaster
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
DE3844247A1 (de) * 1988-12-29 1990-07-12 Minnesota Mining & Mfg Vorrichtung, insbesondere pflaster zum transdermalen verabreichen eines medikaments
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648143B1 (fr) * 1989-06-08 1991-09-06 Rhone Poulenc Chimie Composition comprenant un copolymere silicone thermoplastique et un compose de l'iode, utilisable apres sa mise en forme, pour le traitement des eaux
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5295984A (en) 1989-12-07 1994-03-22 Ultrafem, Inc. Vaginal discharge collection device and intravaginal drug delivery system
US6264638B1 (en) 1989-12-07 2001-07-24 Ultrafem, Inc. Intravaginal drug delivery system and discharge collection device
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
ES2180690T3 (es) * 1990-06-01 2003-02-16 Population Council Inc Preparacion de composiciones que comprenden st1435 para aplicacion topica.
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
WO1992022292A1 (de) 1991-06-10 1992-12-23 Schwarz Pharma Ag Nitroglycerin-pflaster und verfahren zu seiner herstellung
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
DE4223360C1 (enExample) * 1992-07-16 1993-04-08 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5827245A (en) * 1992-07-16 1998-10-27 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising the active subtance 17-β-Estradiol (Anhydrous)
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4328217C2 (de) * 1993-08-21 1996-01-11 Lohmann Therapie Syst Lts Therapeutisches System zur Behandlung der Psoriasis
ATE273035T1 (de) * 1993-11-03 2004-08-15 Clarion Pharmaceuticals Inc Hämostatisches pflaster
US5762955A (en) 1994-02-04 1998-06-09 Smith; Stephen Jay Method for application and maintenance of medication on body tissue
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5531681A (en) * 1995-01-13 1996-07-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
TW592729B (en) * 1995-04-06 2004-06-21 Janssen Pharmaceutica Nv Rate-controlled transdermal administration of risperidone
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6241846B1 (en) 1996-07-03 2001-06-05 Ultrafem, Inc. Apparatus for manufacturing elastomeric articles
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US20030093143A1 (en) * 1999-03-01 2003-05-15 Yiju Zhao Medical device having surface depressions containing nitric oxide releasing compound
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
WO1998043630A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6117441A (en) * 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
DE69938784D1 (de) 1998-07-15 2008-07-03 Brigham & Womens Hospital Polysaccharid-impfstoff gegen staphylokokken infektionen
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
US6056976A (en) * 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
CA2360396A1 (en) 1998-12-30 2000-07-13 Andrew M. Scharenberg Characterization of a calcium channel family
DE19912477A1 (de) * 1999-03-19 2000-09-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System und Verfahren zu seiner Herstellung
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
EP1176959B1 (en) 1999-05-05 2006-03-08 Merck & Co., Inc. Novel prolines as antimicrobial agents
US6348482B1 (en) 1999-05-05 2002-02-19 Merck & Co., Inc. Catechols as antimicrobial agents
US6251432B1 (en) 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
CA2374930C (en) 1999-07-02 2008-08-05 Lts Lohmann Therapie-Systeme Ag Microreservoir system based on polysiloxanes and ambiphilic solvents
CA2384115C (en) 1999-09-03 2016-08-02 Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
DE19949202A1 (de) * 1999-10-13 2001-05-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Acetylsalicylsäure und/oder Salicylsäure
DE19949252B4 (de) * 1999-10-13 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines superfiziellen therapeutischen Systems zur topischen Applikation von Acetylsalicylsäure zur Behandlung von Akne-Erkrankungen und Verfahren zu seiner Herstellung
BR0017026A (pt) 1999-12-15 2003-01-07 Cubist Pharm Inc Lipeptìdeos como agentes antibacterianos
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
ES2527853T3 (es) 2000-03-08 2015-01-30 Massachusetts Institute Of Technology Heparinasa III y sus usos
WO2001078709A2 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
EP1296714B1 (en) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US6696488B2 (en) 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
US7858331B2 (en) * 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
US7700715B2 (en) 2000-11-27 2010-04-20 Minerva Biotechnologies Corporation Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
JP2004525108A (ja) 2000-12-18 2004-08-19 キュービスト ファーマスーティカルズ インコーポレイテッド 精製リポペプチドの調製方法
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7923055B2 (en) * 2001-05-11 2011-04-12 Exogenesis Corporation Method of manufacturing a drug delivery system
WO2002098422A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
EA007232B1 (ru) 2001-08-17 2006-08-25 Коли Фармасьютикал Гмбх Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
AU2002346960A1 (en) 2001-10-06 2003-04-22 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
WO2003039595A2 (en) * 2001-11-07 2003-05-15 Inex Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US7575886B2 (en) 2002-03-11 2009-08-18 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20030049698A1 (en) * 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
JP2007531505A (ja) 2002-11-27 2007-11-08 ミネルバ バイオオテクノロジーズ コーポレーション 癌（ｍｕｃ１）の診断および治療のための技術および組成物
NZ561169A (en) * 2003-01-21 2008-06-30 Thallion Pharmaceuticals Inc Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
WO2004065401A1 (en) 2003-01-21 2004-08-05 Ecopia Biosciences Inc. Polyene polyketides, processes for their production and their use as a pharmaceutical
US7358241B2 (en) * 2003-01-21 2008-04-15 Thallion Pharmaceuticals, Inc. Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions
DE102004002243A1 (de) * 2003-02-07 2004-09-16 Trikon Technologies Limited, Newport Elektrostatische Klemmhalterung für dünne Wafer in einer Vakuumkammer zur Plasmabearbeitung
CN110496230A (zh) 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
WO2004078943A2 (en) * 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
US20050004185A1 (en) * 2003-05-13 2005-01-06 Bachmann Brian O. Polyene polyketides, processes for their production and their use as pharmaceuticals
TWI336627B (en) 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7312339B2 (en) * 2003-06-13 2007-12-25 Thallion Pharmaceuticals Inc. Polyene oxazoles and processes for their preparation
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
WO2004112724A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
ES2661168T3 (es) 2003-07-12 2018-03-27 Accelerate Diagnostics, Inc. Biodetección sensible y rápida
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
CA2535971C (en) 2003-08-20 2018-04-10 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
US7300921B2 (en) * 2003-09-11 2007-11-27 Ecopia Biosciences, Inc. Polyene polyketides and methods of production
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
EP1728077A4 (en) 2004-01-30 2008-11-05 Dana Farber Cancer Inst Inc METHOD FOR DETERMINING AND QUANTIFYING A RADIATION OR GENOTOXIN EXPOSURE
US20070155685A1 (en) * 2004-02-27 2007-07-05 Karl-Hermann Schlingensiepen Pharmaceutical composition
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US7504086B2 (en) * 2004-03-31 2009-03-17 Canon Kabushiki Kaisha Structure and method for releasing substance therefrom
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
EP1629844B2 (en) 2004-07-13 2012-04-18 Bayer Schering Pharma Oy A longterm delivery system with controlled initial burst
JP5230865B2 (ja) * 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
JP5070052B2 (ja) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
DK1797183T3 (da) 2004-09-02 2012-10-01 Univ Yale Regulering af onkogener med mikrornas
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
WO2006034454A1 (en) * 2004-09-23 2006-03-30 The Trustees Of The University Of Princeton Bcl-2 family member and bh-3 only proteins for use in development of peptidomimetics
ES2439229T3 (es) 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
US20060106028A1 (en) * 2004-11-08 2006-05-18 Ecopia Biosciences, Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
AU2005304687B2 (en) 2004-11-11 2012-01-19 The General Hosptial Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
EA012810B1 (ru) 2005-02-25 2009-12-30 Тетралоджик Фармасеутикалс Димерные ингибиторы ингибиторов белков апоптоза (iap)
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
US8859495B2 (en) * 2005-03-30 2014-10-14 Minerva Biotechnologies Corporation Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
JP2008539169A (ja) 2005-04-19 2008-11-13 イーライ リリー アンド カンパニー 疾患における免疫学的介入のための一価および多価合成多糖類抗原
MX2007007184A (es) 2005-05-05 2008-01-14 Antisense Pharma Gmbh Uso de bajas dosis de oligonucleotidos antisentido para tgf-beta, vegf, interleucina-10, c-jun, c-fos o genes e2 de prostaglandina en el tratamiento de tumores.
US7763604B2 (en) * 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
EP1898920A1 (en) * 2005-06-02 2008-03-19 Thallion Pharmaceuticals Inc. Formulation comprising farnesyl dibenzodiazepinone and a pharmaceutically acceptable surfactant
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
UA92498C2 (ru) * 2005-06-16 2010-11-10 Евро-Селтик С.А. Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
EP1906972B1 (en) 2005-07-19 2013-09-11 The University of Tennessee Research Foundation LPA2 receptor agonist for treating diarrhea
CN101267779A (zh) 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CA2617642A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1957093B1 (en) 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
AU2006320327A1 (en) * 2005-12-01 2007-06-07 Duke University Compounds and methods for inhibiting apoptosis
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
US20100129403A1 (en) 2006-06-20 2010-05-27 Transgene S.A. Recombinant viral vaccine
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009000824A (es) * 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
WO2008060791A2 (en) * 2006-10-13 2008-05-22 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
JP2010515434A (ja) 2007-01-05 2010-05-13 マサチューセッツ インスティテュート オブ テクノロジー Ｆｌａｖｏｂａｃｔｅｒｉｕｍｈｅｐａｒｉｎｕｍ由来のスルファターゼを使用する組成物および方法
US20100172882A1 (en) * 2007-01-11 2010-07-08 Glazer Peter M Compositions and methods for targeted inactivation of hiv cell surface receptors
AU2014202051C1 (en) * 2007-02-06 2021-04-22 Columbia Laboratories (Bermuda) Limited Progesterone for the treatment of preterm birth
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
WO2008109773A2 (en) * 2007-03-06 2008-09-12 Cornell Research Foundation, Inc. Chronic obstructive pulmonary disease susceptibility and related compositions and methods
EP2134855A4 (en) 2007-03-12 2011-01-05 Dana Farber Cancer Inst Inc USES OF FANCI AND FANCI MODULATING AGENTS IN PROGNOSIS, DIAGNOSIS AND CANCER THERAPY
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
PL2155248T3 (pl) 2007-04-12 2015-12-31 Brigham & Womens Hospital Inc Celowanie w ABCB5 w terapii nowotworowej
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
BRPI0811621A2 (pt) * 2007-05-17 2014-10-21 Coley Pharm Group Inc Oligonucleotídeos de classe a com potência imunoestimuladora, composição contendo os mesmos e uso da referida composição
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
US8524444B2 (en) 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
US20100291219A1 (en) * 2007-06-21 2010-11-18 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
EP2591787A1 (en) 2007-08-13 2013-05-15 Pfizer Inc Combination motif immune stimulatory oligonucleotides with improved activity
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
US9586035B2 (en) * 2007-12-11 2017-03-07 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
ES2648640T3 (es) 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
US20090233858A1 (en) * 2008-02-26 2009-09-17 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
WO2009111375A2 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
JP2011522515A (ja) 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
CN102076853A (zh) * 2008-05-07 2011-05-25 阿布拉西斯生物科学有限责任公司 通过miRNA增强药物疗法
WO2009151561A2 (en) 2008-06-12 2009-12-17 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
CA2729346A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
EP2323679A4 (en) 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
EP2331103A1 (en) * 2008-09-22 2011-06-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Nuclear factor kappa b pathway inhibitor composition and use of same
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
KR20160017117A (ko) 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
EP2962682B1 (en) * 2008-12-11 2018-03-28 Massachusetts Institute Of Technology Method of making a contact lens drug delivery device
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
NZ594019A (en) * 2008-12-22 2013-08-30 Cubist Pharm Inc Novel antibacterial agents for the treatment of gram positive infections
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010101627A2 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
WO2010127235A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Schweinfurthins and uses thereof
CA2761736C (en) 2009-05-14 2017-09-26 Bayer Animal Health Gmbh Enhanced immune response in avian species
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
JP2012528858A (ja) 2009-06-01 2012-11-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Ｏ−ＧｌｃＮＡｃ転移酵素阻害剤およびその使用
EP3020412B1 (en) 2009-06-16 2017-10-11 The Regents of the University of Michigan An immunogenic composition comprising nanoemulsion inactivated rsv
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
AU2010265863C1 (en) 2009-06-26 2012-11-01 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2456432B1 (en) 2009-07-22 2024-02-28 University of Massachusetts Compositions to reduce oxidative stress
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
RU2012107535A (ru) 2009-07-30 2013-09-10 Антисенс Фарма Гмбх КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
CN105669552A (zh) 2009-08-18 2016-06-15 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
CN105669553A (zh) 2009-08-18 2016-06-15 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
CN102791742B (zh) * 2010-01-19 2014-12-24 动量制药公司 评价肝素制剂
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
KR20130107203A (ko) 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
JP2013526572A (ja) * 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
DE102010050242A1 (de) 2010-10-30 2012-05-03 Schott Ag Wirkstoffverpackung
ES2640474T3 (es) 2010-11-18 2017-11-03 Ischemix Llc Compuestos lipoílicos y su uso para el tratamiento de la lesión isquémica
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
SI2654785T1 (sl) 2010-12-22 2019-06-28 Bayer Intellectual Property Gmbh Ojačan imunski odziv pri govejih vrstah
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
DK2663555T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
US9222085B2 (en) 2011-02-03 2015-12-29 Mirna Therapeutics, Inc. Synthetic mimics of MIR-124
AU2012212023B9 (en) 2011-02-03 2017-01-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-34
RU2598057C2 (ru) 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012122314A2 (en) 2011-03-07 2012-09-13 Accelr8 Technology Corporation Rapid cell purification systems
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
WO2012125623A2 (en) 2011-03-14 2012-09-20 Ludwig Institute For Cancer Research Ltd. Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
BR112013027057A2 (pt) 2011-04-21 2020-08-11 Trustees Of Tufts College composições e métodos para a estabilização de agentes ativos
BR112013030894A2 (pt) 2011-06-01 2016-08-16 Janus Biotherapeutics Inc moduladores do sistema imune
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
AU2012268068B2 (en) * 2011-06-06 2016-10-13 Auritec Pharmaceuticals Drug delivery device employing wicking release window
US9133082B2 (en) 2011-06-14 2015-09-15 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA3149018A1 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013013061A1 (en) 2011-07-19 2013-01-24 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
WO2013020044A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of fibrosis using microrna-19b
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
EP2768945B1 (en) 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
CA2856703A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
CA2862807A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ， インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
US10583169B2 (en) 2012-07-11 2020-03-10 University Of Vermont And State Agricultural College Methylation-controlled J protein (MCJ) for treatment of liver disease and altering mitochondrial metabolism
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
JP2015526471A (ja) 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
US9962448B2 (en) 2012-10-04 2018-05-08 Northeastern University Compounds and methods for targeted immune system delivery
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
CN105358708B (zh) 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
HUE072250T2 (hu) 2013-03-15 2025-11-28 Taris Biomedical Llc Gyógyszeradagoló eszközök gyógyszeráteresztõ résszel
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
EP2970411B1 (en) 2013-03-15 2018-05-09 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US20160052985A1 (en) 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
ES2956840T3 (es) 2013-08-19 2023-12-29 Taris Biomedical Llc Dispositivos de administración de fármacos de múltiples unidades
CN105530867B (zh) * 2013-08-21 2018-11-13 传感技术股份有限公司 用于生物感测分析物的体内保护的药物洗脱
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
WO2015061361A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US10676528B2 (en) 2013-12-06 2020-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
WO2015086489A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
CA2940794C (en) 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
WO2015142865A2 (en) 2014-03-17 2015-09-24 Massachusetts Institute Of Technology Metakaryocidal treatments
US10646541B2 (en) 2014-03-26 2020-05-12 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
WO2015161230A1 (en) 2014-04-19 2015-10-22 Massachusetts Institute Of Technology Methods of reducing kinase inhibitor resistance
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
EP3721875B1 (en) 2014-05-09 2023-11-08 Yale University Particles coated with hyperbranched polyglycerol and methods for their preparation
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
BR112016025045A2 (pt) * 2014-05-30 2017-08-15 Textile Based Delivery Inc sistema de distribuição de fármaco e método de distribuição de um composto biologicamente ativo
US10737078B2 (en) * 2014-06-26 2020-08-11 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
US20170275287A1 (en) 2014-08-22 2017-09-28 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
JP6613304B2 (ja) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗ｃｄ２７６抗体（ｂ７ｈ３）
WO2016046847A1 (en) 2014-09-23 2016-03-31 Council Of Scientific & Industrial Research Metal embedded hydrophilic polymer for drug delivery applications
EP4112076A1 (en) 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
EP3206491B1 (en) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
BR112017007942A2 (pt) * 2014-10-30 2017-12-19 Textile Based Delivery Inc sistemas de liberação
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CA2977050A1 (en) 2015-02-18 2016-08-25 University Of Vermont And State Agricultural College Mcj agonists and uses therefor
EP3268034A4 (en) 2015-03-05 2018-11-14 Northwestern University Non-neuroinvasive viruses and uses thereof
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
WO2016161022A2 (en) 2015-03-30 2016-10-06 Accerlate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3283127B1 (en) 2015-04-15 2020-02-26 University of Massachusetts Compositions and methods for xi chromosome reactivation
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
US10844392B2 (en) 2015-06-05 2020-11-24 Ibio, Inc. Materials and methods for producing endostatin fusion polypeptides in plant cells
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US10633427B2 (en) 2015-06-26 2020-04-28 Prindex S.R.L. Diagnosis and therapy of multiple sclerosis
EP3313519B1 (en) 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
EP3319636A2 (en) 2015-07-10 2018-05-16 University of Vermont and State Agricultural College Mcj inhibitors for use in treating drug-induced diseases and conditions
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
KR20180039162A (ko) 2015-08-20 2018-04-17 아소시아시온 센트로 데 인베스티가시온 코오페라티바 엔 비오시엔시아스-시스 비오구네 간 질환 및 병태를 치료하기 위한 방법 및 조성물
WO2017049192A1 (en) 2015-09-17 2017-03-23 University Of Massachusetts Compositions and methods for modulating fmr1 expression
CN109311982A (zh) 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
US20190046638A1 (en) 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR102611444B1 (ko) 2016-04-08 2023-12-06 지엘바이오, 인크. 플렉틴-1 결합 항체 및 그의 용도
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
EP3454891A4 (en) 2016-05-10 2019-12-25 The Regents of The University of Michigan EMULSION ADJUVANS FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物
WO2017205747A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018005759A1 (en) 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
US10933131B2 (en) 2016-07-26 2021-03-02 Bayer Animal Health Gmbh Increased fertility in bovine species
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
US11160823B2 (en) 2016-11-07 2021-11-02 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US10786471B2 (en) 2017-02-06 2020-09-29 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
EP3615023B1 (en) 2017-04-25 2023-06-21 Ischemix LLC Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
AU2018301500A1 (en) 2017-07-14 2020-01-30 University Of Bath Methods and compositions for treating inflammation
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
US11103460B2 (en) 2017-08-07 2021-08-31 Board Of Regents, The University Of Texas System Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
WO2019129360A1 (en) 2017-12-29 2019-07-04 Laxxon Medical Ag Drug delivery system
WO2019129361A1 (en) 2017-12-29 2019-07-04 Laxxon Medical Ag Method for producing a drug delivery system
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
PL3773537T3 (pl) 2018-04-19 2022-05-23 Tvardi Therapeutics, Inc. Inhibitory stat3
GB2588721A (en) 2018-05-11 2021-05-05 Forte Subsidiary Inc Compositions for the treatment of skin conditions
EP3807644A4 (en) 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
CN121554542A (zh) 2018-08-22 2026-02-24 贝凯恩生物医疗技术有限公司 环孢菌素组合物及使用方法
WO2020047251A1 (en) 2018-08-29 2020-03-05 President And Fellows Of Harvard College O-glcnac transferase inhibitors and uses thereof
EP3860635A4 (en) 2018-10-04 2022-07-06 Rutgers, The State University of New Jersey METHOD OF REDUCING TYPE 2 CYTOKINE MEDIATED INFLAMMATION WITH NEUROMEDIN PEPTIDES
WO2020081737A1 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Compositions and methods for inducing intestinal stem cell regeneration
CN117925571A (zh) 2018-10-19 2024-04-26 德克萨斯州大学系统董事会 工程化长散在元件（line）转座子及其使用方法
KR20210124188A (ko) 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
US12077592B2 (en) 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
KR20210122275A (ko) 2019-01-30 2021-10-08 얀센 파마슈티카 엔.브이. 분자 아형에 기초하여 전립선암을 치료하는 방법
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
EP3923989A1 (en) 2019-03-21 2021-12-22 Mitotherapeutix LLC Multivalent ligand clusters for targeted delivery of therapeutic agents
CA3136618A1 (en) 2019-04-10 2020-10-15 Elevatebio Technologies, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状ｒｎａ組成物及び方法
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
CR20220025A (es) 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
TW202118792A (zh) 2019-07-26 2021-05-16 美商健生生物科技公司 抗hk2嵌合抗原受體(car)
US12496357B2 (en) 2019-07-31 2025-12-16 Yale University Compositions and methods for treating sickle cell disease
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
AU2020334317A1 (en) 2019-08-16 2022-04-07 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
KR20220079878A (ko) 2019-10-07 2022-06-14 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로비시클릭 화합물
ES3074115T3 (es) 2019-10-07 2026-07-17 De Shaw Res Llc Compuestos heterocíclicos de arilmetileno como bloqueadores de los canales de potasio tipo Shaker Kv1.3
WO2021076906A1 (en) 2019-10-17 2021-04-22 Children's Medical Center Corporation Tlr7/8 agonists to enhance immune responses in opioid using individuals
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
MX2022005983A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
EP4069726A4 (en) 2019-12-04 2024-03-20 The Scripps Research Institute GLP2 RECEPTOR AGONISTS AND METHOD OF USE
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
US20230092615A1 (en) 2020-02-21 2023-03-23 Mitotherapeutix Llc Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)
US12678440B2 (en) 2020-02-26 2026-07-14 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
PE20231517A1 (es) 2020-03-13 2023-09-28 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33
EP4138745A4 (en) 2020-04-20 2024-05-29 Avisi Ltd. OPHTHALMIC DEVICE
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
CN115867562A (zh) 2020-05-08 2023-03-28 乔治穆内有限责任公司 Akt3调节剂
CN116322788A (zh) 2020-05-19 2023-06-23 奥纳治疗公司 环状rna组合物和方法
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
CN116782894A (zh) 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
MX2023004395A (es) 2020-10-16 2023-05-22 Univ Georgia Glicoconjugados.
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
AR125210A1 (es) 2021-03-24 2023-06-21 Janssen Biotech Inc Anticuerpos dirigidos a cd22 y cd79b
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
US20250197525A1 (en) 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
WO2022251481A1 (en) 2021-05-26 2022-12-01 The Jackson Laboratory Radiosensitizing compositions and methods
KR20240001192A (ko) 2021-05-28 2024-01-03 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 스피로인돌리논 화합물
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
JP2024534053A (ja) 2021-08-25 2024-09-18 アイバイオ， インク． 抗ｃｄ２５抗体
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
IL312439A (en) 2021-11-05 2024-06-01 Georgiamune Inc Akt3 modulators
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
KR20240111795A (ko) 2021-11-29 2024-07-17 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법
CN118679257A (zh) 2021-12-23 2024-09-20 马萨诸塞大学 用于脆性x相关病症的治疗性治疗
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
AU2022474541A1 (en) 2022-08-18 2025-02-06 Elanco Us Inc. Method for improving growth performance in feedlot cattle
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024112515A1 (en) 2022-11-21 2024-05-30 Northeastern University Click chemistry ligand
AU2023404700A1 (en) 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
EP4634390A2 (en) 2022-12-15 2025-10-22 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
IL323663A (en) 2023-04-06 2025-11-01 Shanghai Argo Biopharmaceutical Co Ltd Nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
AU2024298726A1 (en) 2023-07-27 2026-02-19 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
EP4777612A1 (en) 2023-09-16 2026-07-22 University of Massachusetts Compositions and methods for promoting the generation of pharyngeal foregut endoderm and its derivatives
TW202516009A (zh) 2023-10-10 2025-04-16 大陸商上海舶望製藥有限公司 抑制澱粉樣前體蛋白(app)表達的組合物和方法
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025240947A1 (en) 2024-05-17 2025-11-20 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases
WO2025257173A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257176A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257171A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2026068747A1 (en) 2024-09-26 2026-04-02 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Astrocytic phosphoprotein (pea-15) for use in the treatment and/or prevention of a neuronal disorder
EP4729541A1 (en) 2024-10-16 2026-04-22 Paolo Fiorina Anti- igfbp7 antibodies and uses thereof
WO2026102360A1 (en) 2024-11-08 2026-05-15 University Of Massachusetts Methods and compositions for central nervous system (cns) drug delivery and treatment
WO2026122418A1 (en) 2024-12-02 2026-06-11 Orna Therapeutics, Inc. Circular rna compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
NL297357A (enExample) * 1962-08-31
US3518340A (en) * 1968-04-15 1970-06-30 Dow Corning Method of forming silicone rubber drug carriers
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395815B (de) * 1981-06-29 1993-03-25 Alza Corp Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut
EP0144486A3 (en) * 1983-04-27 1986-05-14 Lohmann Gmbh & Co Kg Controlled-release drugsystem and process for preparing it

Also Published As

Publication number Publication date
DE2135533B2 (de) 1980-06-04
FR2143564B1 (enExample) 1974-04-05
US3854480A (en) 1974-12-17
DE2135533C3 (de) 1981-02-12
FR2143564A1 (en) 1973-02-09
DE2135533A1 (de) 1973-02-01

Similar Documents

Publication Publication Date Title
FR2143564B1 (enExample)
AU2270770A (enExample)
CS148810B1 (enExample)
AU465413B2 (enExample)
AU429630B2 (enExample)
AU5461069A (enExample)
AU5712069A (enExample)
AU417208B2 (enExample)
AU427401B2 (enExample)
AU470661B1 (enExample)
AT308690B (enExample)
AU442357B2 (enExample)
AU442322B2 (enExample)
AU425297B2 (enExample)
AU428074B2 (enExample)
AU438128B2 (enExample)
AU442285B2 (enExample)
AU442535B2 (enExample)
AU428129B2 (enExample)
AU6144869A (enExample)
AR203167Q (enExample)
CS155301B1 (enExample)
AU5228269A (enExample)
AU4923469A (enExample)
AU6261969A (enExample)

Legal Events

Date Code Title Description
PL Patent ceased
PL Patent ceased